Pyridoxamine: A novel treatment for schizophrenia with enhanced carbonyl stress

• DOI: 10.1111/pcn.12613
• Publication Date: 2017-10-24T10:26:35Z
• Authors: Masanari Itokawa; Mitsuhiro Miyashita; Makoto Arai; Takashi Dan; Katsuyoshi Takahashi; Taro Tokunaga; Kayo Ishimoto; Kazuya Toriumi; Tomoe Ichikawa; Yasue Horiuchi; Akiko Kobori; Satoshi Usami; Takeo Yoshikawa; Naoji Amano; Shinsuke Washizuka; Yuji Okazaki; Toshio Miyata
• Keywords: Pentosidine

The aim of this clinical trial was to obtain proof concept for high-dose pyridoxamine as a novel treatment schizophrenia with enhanced carbonyl stress.Ten Japanese patients high plasma pentosidine, which is representative biomarker stress, were recruited in 24-week, open (ranging from 1200 2400 mg/day) administered using conventional antipsychotic regimen. Main outcomes the total change Positive and Negative Syndrome Scale score Brief Psychiatric Rating baseline end at week 24 (or withdrawal).Decreased pentosidine levels observed eight patients. Two showed marked improvement their psychological symptoms. A patient who harbors frameshift mutation Glyoxalase 1 gene also considerable reduction psychosis accompanied moderate decrease levels. greater than 20% assessment scale drug-induced Parkinsonism occurred four Although there no severe suicide-related ideation or behavior, Wernicke's encephalopathy-like adverse drug reactions two completely suppressed by thiamine supplementation.High-dose add-on was, part, effective subpopulation stress. Further randomized, placebo-controlled trials careful monitoring will be required validate efficacy these